Al-Mrabeh · Cell metabolism 2020 · randomized controlled trial subgroup analysis · n=?

Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss.

Cited 161 times in the scientific literature.

Level 2 - randomized trial

Subgroup analysis within a randomized controlled trial

PubMed 31866441 · doi:10.1016/j.cmet.2019.11.018 · record verified 2026-08-28

What was done

Investigators measured the contributions of hepatic VLDL1-triglyceride production rates and VLDL1-palmitic acid content to intra-pancreatic fat accumulation and first-phase insulin response. The study was conducted in a subgroup of participants from the Diabetes Remission Clinical Trial across 24 months of follow-up after dietary weight loss.

What was found

The abstract provides no numerical data, effect sizes, or p-values. Liver fat, VLDL1-triglyceride production, and intra-pancreatic fat decreased after weight loss and remained normalized at 24 months in participants maintaining remission. First-phase insulin response remained increased only in those in remission. Participants who relapsed showed greater increases in VLDL1-triglyceride and VLDL1-palmitic acid content, re-accumulated intra-pancreatic fat, and lost first-phase insulin response by 24 months.

Why it matters

The findings demonstrate a mechanistic pathway linking disordered hepatic lipid export and pancreatic fat re-accumulation to beta-cell dysfunction in diabetes relapse.

Limits

The abstract does not state the sample size, baseline patient characteristics, or numerical measurements. As an observational comparison between remitters and relapsers within an intervention cohort, residual confounding cannot be excluded.

Cited by